ASSESSMENT OF DISABILITY (EDSS) AND LIVER COMPLICATIONS IN MULTIPLE SCLEROSIS PATIENTS TREATED BY RECIGEN IN COMPARISON WITH BETAFERON

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

FOROUGHIPOUR MOHSEN; ETEMADI MOHAMMAD MAHDI; NIKKHAH KARIM; AFZALNIA AZADEH; HAZRATI NAZANIN; EBADI FATEMEH; FARZADFARD MOHAMMAD TAGHI

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Medical Journal of Mashhad University of Medical Sciences Year:2014 | Volume:57 | Issue:5 Page(s): 669-675

Download Full-Text

Persian Verion

View:

1,832

Download:

Cites:

Information Journal Paper

Title

ASSESSMENT OF DISABILITY (EDSS) AND LIVER COMPLICATIONS IN MULTIPLE SCLEROSIS PATIENTS TREATED BY RECIGEN IN COMPARISON WITH BETAFERON

Author(s)

Keywords

MULTIPLE SCLEROSISQ2

INTERFERON-BETAQ2

DISABILITY EVALUATIONQ2

ADVERSE EFFECTSQ3

Abstract

Introduction: MULTIPLE SCLEROSIS (MS) is a chronic neurologic disease. At the present time, Rebif, which is the most effective drug in treatment of MS after Avonex, is used to prevent relapses. Recigen is Iranian generation of Rebif. It is almost a year since the entry of Recigen into our pharmaceutical market and it is virtually superseding American Rebif, but no study has been performed on efficacy and hepatic side effects of this drug. The aim of this study is to compare the efficacy and side effects of Betafron and Recigen in medical university of mashhad in 1389-1390.Methods: This was a single blind study conducted in neurology department of Qaem hospital on MS patients who fulfil criretia for pharmacotherapy indications. EDSS, complications and symptoms were compared in Betafron and Recigen group. Demographic data were analyzed using SPSS software.Results: Demographic characteristics (like age and sex) were similar in both groups with no significant differences. There were no significant differences in EDSS and hepatic side effects in both Betafron and Recigen groups (p=0.134). Relapse rate was significantly lower in Betafron group (p=0.03).Conclusion: It seems both drugs has the same rate of side effects and EDSS scores. Recigen has similar efficacy in comparison with Betafron, though it cannot prevent relapses in short time.

Cites

No record.

References

No record.

Cite

APA: Copy

FOROUGHIPOUR, MOHSEN, ETEMADI, MOHAMMAD MAHDI, NIKKHAH, KARIM, AFZALNIA, AZADEH, HAZRATI, NAZANIN, EBADI, FATEMEH, & FARZADFARD, MOHAMMAD TAGHI. (2014). ASSESSMENT OF DISABILITY (EDSS) AND LIVER COMPLICATIONS IN MULTIPLE SCLEROSIS PATIENTS TREATED BY RECIGEN IN COMPARISON WITH BETAFERON. MEDICAL JOURNAL OF MASHHAD UNIVERSITY OF MEDICAL SCIENCES, 57(5), 669-675. SID. https://sid.ir/paper/51249/en

Vancouver: Copy

FOROUGHIPOUR MOHSEN, ETEMADI MOHAMMAD MAHDI, NIKKHAH KARIM, AFZALNIA AZADEH, HAZRATI NAZANIN, EBADI FATEMEH, FARZADFARD MOHAMMAD TAGHI. ASSESSMENT OF DISABILITY (EDSS) AND LIVER COMPLICATIONS IN MULTIPLE SCLEROSIS PATIENTS TREATED BY RECIGEN IN COMPARISON WITH BETAFERON. MEDICAL JOURNAL OF MASHHAD UNIVERSITY OF MEDICAL SCIENCES[Internet]. 2014;57(5):669-675. Available from: https://sid.ir/paper/51249/en

IEEE: Copy

MOHSEN FOROUGHIPOUR, MOHAMMAD MAHDI ETEMADI, KARIM NIKKHAH, AZADEH AFZALNIA, NAZANIN HAZRATI, FATEMEH EBADI, and MOHAMMAD TAGHI FARZADFARD, “ASSESSMENT OF DISABILITY (EDSS) AND LIVER COMPLICATIONS IN MULTIPLE SCLEROSIS PATIENTS TREATED BY RECIGEN IN COMPARISON WITH BETAFERON,” MEDICAL JOURNAL OF MASHHAD UNIVERSITY OF MEDICAL SCIENCES, vol. 57, no. 5, pp. 669–675, 2014, [Online]. Available: https://sid.ir/paper/51249/en

Related Journal Papers